An observational study in Idiopathic Pulmonary Fibrosis (IPF) and Sarcopenia, sponsored by Mersin University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-17.
Sponsored by Mersin University · Observational
Sarcopenia negatively affects the prognosis of chronic diseases. However, the importance of sarcopenia in patients with idiopathic pulmonary fibrosis (IPF) has been less emphasized. The aim of the study is to determine the prevalence of sarcopenia in patients with IPF and to evaluate the impact of sarcopenia on quality of life and disease progression.
This study was designed as a descriptive cross-sectional. The study included patients diagnosed with IPF. Hand dynamometry and bioelectrical impedance analysis (BIA) were used to for diagnose of sarcopenia. Pulmonary function tests, maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) measurements were examined. The 6-minute walk distance (6MWD) and 4-meter walking speed were recorded. The St. George Respiratory Questionnaire (SGRQ) was used to assess quality of life. All patients were evaluated for progressive disease.
The study was designed as a cross-sectional study.
551 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 117 are open to participants now.
This study's enrollment of 60 is below the median of 158 across 154 observational studies indexed under Idiopathic Pulmonary Fibrosis.
Browse Idiopathic Pulmonary Fibrosis studies →Mersin University is the lead sponsor of 173 studies on the registry; 48 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients included in the study were those diagnosed with IPF according to the ATS/ERS/JRS/ALAT 2022 guidelines and who applied to the Department of Pulmonary Diseases at Mersin University Faculty of Medicine.
Exclusion Criteria:
The prevalence of sarcopenia was investigated in patients with IPF who met the inclusion and exclusion criteria. The relationship between sarcopenia and quality of life and disease progression in patients with IPF was evaluated.
Hand Grip Strength
Hand Grip Strength (kg)- Grip strength measurement using a hand dynamometer
Time frame: through study completion, an average of 1 year
SMI (skeletal muscle mass index)
SMI (skeletal muscle mass index) (kg/m2) - SMI measurement using the Bioelectrical Impedance Analysis (BIA) device
Time frame: through study completion, an average of 1 year
Forced Expiratory Volume in 1 second (FEV1)
Measurement of FEV1 for the assessment of pulmonary function
Time frame: through study completion, an average of 1 year
Forced Vital Capacity (FVC)
Measurement of FVC for the assessment of pulmonary function
Time frame: through study completion, an average of 1 year
Diffusing Capacity of The Lungs for Carbon Monoxide (DLCO)
Measurement of DLCO for the assessment of pulmonary function.
Time frame: through study completion, an average of 1 year
Total Lung Capacity (TLC)
Measurement of TLC for the assessment of pulmonary function.
Time frame: through study completion, an average of 1 year
Respiratory Muscle Strength
Measurement of maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) for assessment of respiratory muscle strength
Time frame: through study completion, an average of 1 year
Six Minute Walk Test (6MWT)
Distance walked in six minutes (m)
Time frame: through study completion, an average of 1 year
Gait speed
4-meter walking speed (m/s)
Time frame: through study completion, an average of 1 year
St. George's Respiratory Questionnaire (SGRQ)
The questionnaire is designed to measure quality of life. It consists of symptom, activity, impact, and total scores. Each score ranges from 0 to 100. High scores indicate lower quality of life.
Time frame: through study completion, an average of 1 year
Progressive Disease
Examination of all participants from clinical, physiological, and radiological perspectives
Time frame: through study completion, an average of 1 year
Body Mass Index ( BMI)
kg/m2
Time frame: through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Idiopathic Pulmonary Fibrosis→
Mersin University